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‡Centro de Cien̂cias da Saud́e (CCS), Universidade Federal de Santa Catarina (UFSC), 88040-900 Florianoṕolis, Brazil
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ABSTRACT: In the pharmaceutical area, some drugs exhibit
physicochemical properties that adversely affect the formula-
tion processes for bioavailability and effectiveness. Nevirapine
(NVP) is an antiretroviral drug that presents low aqueous
solubility, which directly impacts its bioavailability. Among all
possible modifications, multicomponent crystals, such as
cocrystals and eutectic compositions, have been successfully
used to improve the solubility of drugs. In this work, the
propensity of the formation of multicomponent systems of
NVP with seven possible coformers were predicted and tested:
salicylic acid (SA), 3-hydroxybenzoic acid (3HBZC), 4-
hydroxybenzoic acid (4HBZC), saccharin (SAC), theophyl-
line (THEO), caffeine (CAF), and urea (URE). Results
indicate that NVP−SA, NVP−SAC, NVP−3HBZC, and NVP−4HBZC are cocrystals, whereas NVP−THEO and NVP−CAF
are eutectic materials, and NVP−URE is a solid physical mixture. A temperature-dependent disorder behavior was identified for
NVP−SA cocrystal. Dissolution studies for the eutectic materials are reported, evidencing that these materials exhibit a
significant increase in NVP dissolution kinetics.
■ INTRODUCTION
Nevirapine (NVP) (11-cyclopropyl-5,11-dihydro-4-methyl-6H-
dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one)1,2 is an antiretrovi-
ral drug used for the treatment of AIDS/HIV-1 infection.
According to the Biopharmaceutics Classification System
(BCS), NVP is classified as a Class II drug; i.e., it presents low
water solubility and high permeability in the gastrointestinal
tract.3 The low water solubility is a challenge during the
formulation of the drug, directly affecting its bioavailability.
High doses are often necessary to guarantee its effectiveness,
increasing possible adverse side effects.
Crystallization methods can be used to obtain different crystal
forms of NVP in order to improve its dissolution and,
consequently, its bioavailability. Cocrystals and eutectics are
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among possible crystalline modifications that can be used to
improve the physicochemical and pharmaceutical properties of
drugs.4−10 Cocrystals have been successfully used in the
pharmaceutical area to produce solid forms of a drug with
improved properties.11−16 Caira and co-workers reported the
crystal structure of several NVP cocrystals with improved
dissolution rates compared to pure NVP crystals.17 So far,
eutectic systems with NVP have not been described in the
literature. However, for other drugs, pharmaceutical eutectic
systems have shown an accomplishment in the production of
solid forms with improved properties, including dissolu-
tion.8,18−20
Pharmaceutical cocrystals are formed with neutral molecules
of an active pharmaceutical ingredient (API) and any other
neutral molecule in a well-established stoichiometry.21,22
Cocrystals are single-phase compounds, exhibiting a new
crystalline structure, which is different from that of parent
components. Further, this new phase exhibits its own
physicochemical properties, also different from the properties
exhibited by parent components (Figure 1). In turn, physical
mixtures and eutectic systems can be described as multiphase
compounds. They exhibit a mixture of two or more phases that
do not interact to form a new structure, such as in cocrystals
(Figure 1). Physical mixtures exhibit the physicochemical
properties of both parent compounds. However, at certain
ratios, the eutectic mixture exhibits a lower melting point than
the parent compounds and may also show differences in other
physicochemical properties.10 Eutectic system formation occurs
when the components are miscible in a liquid state and
immiscible in the solid state.23 When two components, A and B,
in the liquid phase are cooled, the solidification of both
components and formation of a mixture of solid phases, α and β
occur. It can be concluded that an eutectic material has been
obtained when it presents a single melting point which is
dependent on the composition of the eutectic.
In order to produce multicomponent materials of NVP
presenting better properties, a screening study was herein
performed. The coformer molecules were selected based on the
presence of carboxyl and amide groups that could disrupt the
amide−amide dimer motif observed in the pure NVP structure,
and that had delocalized planar structures that could stack with
the pyridine fragments in NVP molecules. Thus, seven
coformers, salicylic acid (SA) and its two isomers3-
hydroxybenzoic acid (3HBZC), 4-hydroxybenzoic acid
(4HBZC)saccharin (SAC), caffeine (CAF), theophylline
(THEO), and urea (URE) (Scheme 1), were selected and used
in this screening of multicomponent forms of NVP. These
materials were prepared through the liquid-assisted grinding
(LAG) method, which is well-accepted for pharmaceutical
cocrystal screening.24 Solid-state characterization was per-
formed through single-crystal and powder X-ray diffraction
with conventional and synchrotron radiation at different
temperatures, differential scanning calorimetry, and solid-state
nuclear magnetic resonance.
The crystal structure of NVP−SA and NVP−SAC cocrystals
have been previously described by Caira and co-workers,17 and
they were selected for reproducibility purposes and to compare
with the 3HBZC and 4HBZC isomers behavior. Besides, a full
Figure 1. Representation of the structural organization in multicomponent solid forms of an API.
Scheme 1. Bidimensional Representation of the Seven Coformers Used in the Cocrystal Screening
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characterization for both multicomponents, NVP−SA and
NVP−SAC, has been done. NVP−SA crystals presented a
temperature-dependent disorder. NVP−URE and NVP-4-
HBZC have been described by Nalte and co-workers.25
However, they have tested the cocrystal formation of these
multicomponent forms only through melting point determi-
nation using an open capillary tube method. NVP−(3HBZC,
4HBZC, THEO, CAF, URE) multicomponent crystals
structures were not found at the CSD database.
■ EXPERIMENTAL SECTION
Cocrystallization Prediction. In order to predict the propensity
formation of NVP cocrystals, two Cambridge Crystallographic Data
Centre (CCDC) tools were used: the screening by molecular
complementarity (MC)26 and the hydrogen-bond propensity
(HBP).27 Both tools are available at CSD Mercury software version
4.0.0.
TheMC is a tool developed and validated by L. Fab́iań, whose output
is a simple pass or fail answer to the formation of the cocrystals. This is
based on the premise that molecules tend to crystallize together only if
they have similar molecular properties. Therefore, a few shape and
polarity descriptors are calculated for the API and the coformer, and to
pass the MC test, they have to differ by less than a threshold value that
Fab́iań established from a statistical analysis performed at the CSD.
The HBP tool was originally developed as a knowledge-based
method to assess the risk of polymorphism for a given compound,
though it can also be used to evaluate cocrystal formation. On the basis
of an automated statistical analysis of hydrogen bonding patterns, the
HBP method determines interaction likelihoods for all the possible
hydrogen-bonding interactions that can be formed with the set of
functional groups present in the specific chemical environment
analyzed. We have built three different mol2 files to analyze the seven
cocrystal systems, one for each component (NVP and coformer) and
another file containing both together. In this way, we can judge how
likely a cocrystal is to form (multicomponent score) as the difference of
the most likely interaction in pure NVP or in pure coformer and, the
most likely cocrystal interaction. The HBP fitting data were generated
using the truncate data generation mode.
Sample Preparation. The liquid-assisted grinding method was
used to prepare the multicomponent materials containing NVP. Seven
different coformers were tested: salicylic acid (SA), 3-hydroxybenzoic
acid (3HBZC), 4-hydroxybenzoic acid (4HBZC), saccharin (SAC),
caffeine (CAF), theophylline (THEO), and urea (URE). Experimental
details are available in Supporting Information. Powder samples were
characterized by solid-state analytical techniques.
Powder X-ray Diffraction (PXRD). Pure NVP and seven pure
coformers were characterized by PXRD, which was carried out by using
conventional (PXRD) and synchrotron (SPXRD) sources.
PXRD analyses were carried out in Rigaku automatic X-ray
diffractometer for powder diffraction (Ultima IV) by using Cu−Kα
radiation source (λ = 1.5418 Å). The Kβ radiation was filtered. Data
were recorded at tube voltage of 40 kV and a current of 30 mA. Samples
were placed on Bragg−Brentano (flat plate) geometry.28,29 The D/Tex
Ultra detector operated at 2θ/θ mode in continuous scanning at a
scanning rate of 20°/min. Experiments were performed at room
temperature, at step-size 0.01° in the angular range 5−35° 2θ.
SPXRD experiments were performed at the XRD1 beamline at the
Brazilian Synchrotron Light Laboratory (LNLS, Campinas, Brazil).30
This beamline is dedicated to X-ray powder diffraction analysis. It is
composed of the three-circle heavy-duty diffractometer (Newport) and
the MYTHEN 24K detector system (Dectris). Experiments were
conducted in Debye−Scherrer geometry. Samples were placed in
borosilicate capillaries (0.7 mm diameter). Experiments were
conducted at 8 keV radiation, and data were collected at the range
300 to 108 K. Samples were cooled down using CryojetHT from
OXFORD Instruments, at a cooling rate of 2 K·min−1. Equipment
configuration allowed collecting one diffraction pattern every 1.2 K.
Radiation wavelength was set based on Silicon standard (NIST
SRM640D) data, which were collected at the end of each experiment.
Single-Crystal X-ray Diffraction (SXRD). SXRD experiments for
NVP-SA were performed in a Bruker D8 Venture diffractometer
(Photon 100 CMOS detector and MoKα radiation from Incoatec
micro source) and for NVP-4HBZC in a Bruker D8 Venture
diffractometer equipped with a CMOS Photon 100 detector using
CuKα radiation. The diffraction images were analyzed (indexed,
integrated, and scaled) in the Apex3 software.31 Crystal structures were
solved through the direct methods and refined by Full-matrix-block
least-squares in the SHELX-15 software.32 All non-hydrogen atoms
were anisotropically refined, and all hydrogen atoms were placed in
idealized geometries according to the riding model. Connectivity
restraints and rigid body were used to describe salicylic acid molecule
disorder at room temperature.
Differential Scanning Calorimetry (DSC). DSC curves were
obtained in a DSC 204 F1 Phoenix NETZSCH calorimeter. In order to
characterize the multicomponent materials, 5 mg of each sample was
placed in a hermetically sealed aluminum crucible and scanned at a
temperature range of 50 to 300 °C, using a heating rate of 10 °C·min−1.
For the construction of phase diagrams, different compositions of
eutectic systems were scanned at a temperature range of 50−300 °C,
using a heating rate of 3 °C·min−1. All samples were scanned in a
nitrogen air atmosphere (70 mL·min−1), and an empty and sealed
aluminum crucible was used as a reference. The equipment was
calibrated by using indium (mp 156.6 °C and Hm 28.54 J·g−1) and zinc
(mp 419.6 °C). Data were processed in the NETZSCH Proteus
software.
Solid-State NMR. 13C CP/MAS ssNMR studies were performed
using ramp CP/MAS pulse sequence33,34 with proton decoupling
during acquisition at room temperature. All experiments were carried
out in a Bruker Avance II spectrometer operating at a resonance
frequency of 300.13 MHz for protons and 75.46 MHz for carbons. The
spectrometer was equipped with a 4 mmMAS probe. The spinning rate
was set at 10 kHz, the recycling delay was 350 s, and the contact time
during CP was 2 ms. To obtain an adequate signal-to-noise ratio, 64−
192 transients were collected. The SPINAL-6435 pulse sequence was
used for heteronuclear decoupling during acquisition (40.96 ms)
satisfying proton field H1H ω1H/2π = γH H1H/2π = 65.8 kHz.
Glycine was used as an external reference (δCOOH= 176.46 ppm) and
set to the Hartman-Hahn condition in CP/MAS experiments.
Quaternary carbon edition spectra of all samples were recorded
through a nonquaternary suppression (NQS) sequence; the 1H and 13C
radiofrequency (rf) fields were removed during 40 μs after CP and
before the acquisition. Such delay allows carbonmagnetization to decay
because of 1H−13C dipolar coupling, which results in spectra wherein
CH and CH2 are substantially removed.
36
Dissolution Profile. Dissolution profiles were determined for
NVP−THEO, NVP−CAF, and NVP raw material. The dissolution
profiles were obtained in a Distek dissolution system Evolution 6100. It
was used a USP apparatus II under stirring at 50 rpm. Experiments were
carried in two different dissolution media: water and HCl 0.1 N. A
volume of 900 mL of the mediumwas placed in a vessel and maintained
at 37 ± 0.5 °C during all experiments. For each sample, 200 mg of
sample was dispersed in the medium. Experiments were performed in
triplicate. AnOpt-Diss 405 system (Distek), a multichannel, fiber optic-
based UV spectrometer system, was attached to the dissolution system.
It enabled us to collect the absorbance values and automatically
calculated the percentage of dissolved material in each vessel. The
system was set up to collect data every 30 s in the first 15 min, every 60 s
in the following 45 min, and every 10 min in the second hour.
Intrinsic Dissolution Rate. Intrinsic dissolution rate was
calculated for NVP−THEO, NVP−CAF, and NVP raw material. A
mass of 100 mg of each sample was placed into the 0.8 cm diameter
cavity in the apparatus. The powder was compressed under a pressure of
1600 psi for 60 s. The apparatus containing the compressed pellet was
placed in 900mL ofmedium. Two different media were used: water and
HCl 0.1 N. Previous experiments were performed to confirm that no
phase transition occurred under pressure nor in the different media.
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■ RESULTS AND DISCUSSION
A liquid-assisted grinding method with NVP and seven different
coformers (salicylic acid (SA), 3-hydroxybenzoic acid
(3HBZC), 4-hydroxybenzoic acid (4HBZC), saccharin
(SAC), caffeine (CAF), theophylline (THEO), and urea
(URE)) was tested to obtain multicomponent materials. Four
cocrystals confirmed by powder X-ray diffraction were obtained,
NVP−SA, NVP−3HBZC, NVP−4HBZC, and NVP−SAC.
Two eutectic materials, NVP−CAF and NVP−THEO, were
confirmed and characterized through solid-state analytical
techniques. The remaining one, NVP−URE, resulted in a
solid physical mixture. The dissolution properties of the eutectic
materials were investigated.
Cocrystallization Prediction Was Performed Using
CCDC Tools. The molecular complementarity screening
(MC) for the NVP API and the seven coformers was calculated
(Table 1 and Table S1). Detailed information for all calculated
descriptor values is in Table S2. The results indicate that most of
the selected coformers are likely to formNVP cocrystals. Urea is
not expected to crystallize with NVP molecules. This is because
the urea molecule has a fraction of N and O atoms overall non-
hydrogen atoms present in the molecule, three times higher than
NVP. While if SA is selected as a coformer, the propensity to
crystallize with NVP depends on the SA conformer used from
the CSD. Furthermore, the small (S) axis of the imaginary
calculated rectangular box that enclosed theUREmolecule (MC
method uses this box to define the shape and size descriptors) is
much shorter than that calculated for NVP. None of these two
descriptors pass the permitted MC threshold (Table S2). For
the SAmolecule, the difference in the S axis with NVP is close to
the threshold, and a slight rotation of the hydrogens in the
molecule modifies the length in the S axis leading to pass or fail
of the MC test.
The HBP analysis is available for polymorph assessment for
one single molecule. Here, we have calculated HBP to assess the
propensity of H-bonding in a multicomponent formation, AB,
where A is the NVP and B is the coformer. All hydrogen-bond
donor and acceptor atoms of both molecules are considered.
The propensity is calculated for all donor···acceptor interactions
between A−A, B−B, A−B, and B−A. It was considered the
maximum propensity in each case (Table 2). A multicomponent
score was calculated through the difference of the maximum
propensity for heterointeractions, A−B or B−A, which are
probabilities (from 0 to 1) of each possible H-bond, and the
maximum propensity for H-bond homointeractions, A−A or B−
B. Thus, a positive and higher multicomponent score means a
greater propensity to form heterointeractions, and consequently,
a higher probability to obtain multicomponent structures.
Considering the nature of cocrystal and eutectic structures,
heterointeractions are observed in cocrystals and in the
interdomain surface in eutectics; therefore, high positive
multicomponent scores must be related to cocrystal prediction.
We should note that organic eutectics are conglomerates of
lattice structures of the components where heterointeractions
only appear in the interphase between domains.
The multicomponent scores obtained for the NVP cocrystals
with the seven coformers are shown in Table 2 using a traffic
light analogy. SA, 3HBZC, and 4HBZC, in green, are the most
likely molecules to form NVP multicomponent solids. It agrees
with our experimental results. On the other side, CAF exhibits
the highest negative score. This molecule does not have any H-
bond donors, which affects the propensity results. Finally, SAC,
THEO, and URE, in yellow, exhibit intermediate multi-
component score values. Only one-phase multicomponent
materials should be predicted by the HBP tool for SAC,
THEO, and URE because only in these solids H-bond
interactions between the components are expected.
Powder X-ray Diffraction (PXRD). Analysis was carried
out in order to identify the crystalline phases obtained after
sample preparation. Diffraction patterns of all prepared samples
were compared to diffraction patterns of its parental
compounds. PXRD results indicate that NVP−SA, NVP−
3HBZC, NVP−4HBZC, andNVP−SAC samples correspond to
new phases, whereas NVP−THEO, NVP−CAF, and NVP−
URE are a mixture of NVP and coformer phases (Figure S1).
Furthermore, NVP−SA and NVP−SAC PXRD data were also
compared to structures reported at the CSD. Comparing NVP−
SAC with the reported structure (CSD refcode: LATQOO),17
one can conclude that we have obtained the same crystallo-
graphic phase recorded by Caira et al. (Figure S2). However, a
comparison of NVP−SA and the reported cocrystal (CSD
refcode: LATQUU)17 evidence some differences. It is important
to mention that PXRD data were collected at room temperature
(RT) and Caira’s reported structure was determined at low
temperature (100 K).17 Significant differences were observed at
approximately 12.5° and in the region between 15° and 20°,
which could be evidence of structural changes with the
temperature (Figure S3). Further characterization was per-
Table 1. Molecular Complementarity, MC, Results for
Nevirapine Cocrystal Screening
Table 2. HBP Results for Multicomponent Analysisa
aComponent A refers to the NVP molecule.
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formed in order to understand these differences in the diffraction
patterns, and the results will be presented later.
Solid-State NMR. Analysis was carried out in NVP−SA,
NVP−SAC, NVP−THEO, NVP−CAF, and NVP−URE
samples. The 13C CP/MAS spectra of NVP and SA are shown
in Figure 2. The carbon assignments and chemical shift values in
all spectra are given in Table S3. The assignments were done
considering the NQS spectra. The 13C CP/MAS spectrum did
not show multiplicity in the resonance lines in both cases, thus
indicating only one molecule per asymmetric unit. The 13C CP/
MAS spectrum of NVP−SA is also shown in Figure 2. Clear
changes in the chemical shifts of signals can be found by
comparing NVP−SA with the coformers. Thus, it is possible to
ensure the existence of an interaction between NVP and SA.
The 13C CP/MAS spectra of the NVP−SAC sample exhibit
changes in the chemical shift of the signals regarding the spectra
of the precursors. This is an indication of modifications in the
environments of bothmolecules and the presence of interactions
between them (Figure S4). On the other hand, the ssNMR 13C
spectra for NVP−THEO, NVP−CAF, and NVP−URE are the
addition of the spectra of NVP and the respective coformer
(Figure S4). This result evidences that there is no interaction
between the pure compounds; i.e., the result of the
cocrystallization process is the physical mixture of the
precursors. These results agree with that obtained by PXRD.
Differential Scanning Calorimetry (DSC). Analysis was
carried out in all multicomponent samples. As expected, NVP−
SA, NVP−3HBZC, NVP−4HBZC, and NVP−SAC cocrystals
were also confirmed through DSC. Although Nalte and co-
workers25 have described NVP−URE as a cocrystal, with a
different melting point, the DSC results indicate that this sample
consists of a physical mixture. In the cases of NVP−THEO and
NVP−CAF, interesting thermal behavior was noticed and is
commented on in the sequence. All curves are available in the
Supporting Information (Figure S5).
According to PXRD and ssNMR analysis, one can conclude
that the NVP−THEO and NVP−CAF are simply physical
mixtures of NVP and coformer. However, DSC results showed
that NVP−THEO andNVP−CAF behavior is not that expected
for physical mixtures. In the case of the NVP−THEO, the
multicomponent system presented two thermal events at 223.6
and 234.1 °C; however, NVPmelts at 247.8 °C, whereas THEO
melts at 274.7 °C. Since the mixture melts in a temperature
below the melting point of the pure compounds, the data
exhibited for NVP−THEO would allow thinking that this could
be a eutectic system. NVP−CAF presented a similar behavior.
The DSC analysis for the NVP−CAF sample showed thermal
events at 163.1 °C, 204.4 °C, and 212.8 °C. The pure CAF
presented twomain events at 155.8 and 238.6 °C. The first point
was consistent with data in the literature, which indicates a phase
transition for caffeine at 153 °C,37 whereas the second event
corresponds to the melting point of CAF. Thus, the event
occurring at 163.1 °C corresponds to the phase transition of
CAF; however, the following two events are not related to pure
CAF or to pure NVP. Adding this evidence to PXRD and
ssNMR results, one can conclude that NVP−CAF could also be
a eutectic system.
In order to investigate the eutectic systems, different
compositions of NVP−THEO and NVP−CAF were analyzed
through DSC. Eleven curves were obtained for each system
(Figure S6), corresponding to pure NVP, pure coformer
(THEO or CAF), and samples at ratios of 1:9, 2:8, 3:7, 4:6,
5:5, 6:4, 7:3, 8:2, and 9:1 (m/m). Samples were prepared by a
simple mixture of components in the absence of solvent. Both
systems, NVP−THEO and NVP−CAF, present similar
behaviors. For each set of a mixture, there is a curve where
only one event appears, and it corresponds to the eutectic
composition of the system. In all the other curves, there is an
event corresponding to the melt of the eutectic, followed by a
second event. This second event corresponds to the excess of
NVP or coformer, which has a variable melting point according
to the composition. In the case of NVP−THEO, the eutectic
composition occurs in a ratio of 7:3 (m/m), presenting an
eutectic temperature of 224.1 °C approximately. In the ratios of
8:2 and 9:1, the second event corresponds to the melting of
NVP, whereas in the ratios of 1:9, 2:8, 3:7, 4:6, 5:5, and 6:4, it
corresponds to themelting point of THEO (Figure S6a). For the
NVP−CAF system, the eutectic composition occurs in a ratio of
3:7 (m/m), with a eutectic temperature of 203.4 °C
approximately. In ratios of 1:9 and 2:8, the second event
corresponds to themelting point of CAF, whereas in the ratios of
4:6, 5:5, 6:4, 7:3, 8:2, and 9:1, it corresponds to NVP (Figure
S6b).
Figure 2. 13C CP/MAS spectra of NVP−SA, SA, and NVP. Carbon numbering adopted throughout the study is highlighted.
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On the basis of the thermal curves obtained at different
compositions, phase diagrams for both systems were obtained
(Figure 3). In the case of NVP−THEO, one can clearly
distinguish the liquidus and solidus lines. The solidus line
corresponds to the constant curve at approximately 222 °C. This
line marks the temperature where the eutectic mixture starts to
melt, that is, the eutectic temperature. In the case of NVP−CAF,
an eutectic temperature around ∼202 °C is present in all
compositions, marking the solidus line for this diagram, and
consequently, the eutectic temperature. In addition, a line
around 153 °C can be seen and corresponds to the phase
transition of CAF. The intersection of the liquidus lines and the
solidus line in each diagram allows us to obtain the eutectic
composition in each system. Using the linear fitting, it was
possible to determine the eutectic composition of 70:30 (% m/
m) for NVP−THEO and 36:64 (% m/m) for NVP−CAF.
Single Crystal X-ray Diffraction. In order to determine the
crystalline structure of the four cocrystals obtained, slow
evaporation experiments were carried out for all of them
attempting to obtain good single crystals for SCXRD experi-
ments. Although single crystals were obtained for NVP−SA and
NVP−4HBZC, so far it has not been possible to grow crystals of
suitable quality to carry out SCXRD experiments for NVP−SAC
and NVP−3HBZC. Crystallographic parameters are summar-
ized in Table S4. Structures of the NVP−SA multicomponent at
room temperature (RT) and 100 K (LT) present the same space
group, P1̅; however, the second has twice the volume than the
first, and while the NVP−SA at RT has z′ equal to 1, the LT
structure has z′ equal to 2. Both present a stoichiometry NVP
coformer 2:1. Salicylic acid molecules at RT are positioned in a
center of symmetry that confers disorder to them (Figure 4).
The precession images (Figure S7) verify the confidence of the
assigned unit cell in both cases, since the unit cell at room
temperature could not explain all the observed reflections in the
experiment at low temperature and corroborates the loss of the
inversion center of symmetry at the NVP dimer and over the
salicylic acid molecules (Figure 5 and Figure 6), which doubles
the asymmetric unit and, therefore the unit cell volume (Table
S5). NVP−4HBZC crystallizes in the C2/c monoclinic space
group, and it presents one nevirapine molecule and one 4-
hydroxybenzoic acid molecule in the asymmetric unit (Figure
7). Nevirapine molecules in the title structures do not present
significant differences in bond distances and angles. They display
a “butterfly” conformation with angles between the pyridine
rings at the range (119.9−126.4°) in agreement with pure NVP
structure (CSD refcode: PABHIJ01)38 121.9°.
Figure 3. Phase diagrams for NVP−THEO and NVP−CAF systems. The arrows indicate the eutectic points in each system. In the NVP−CAF phase
diagram, besides the liquidus and solidus lines, it is also possible to see the caffeine phase transition (black dots).
Figure 4. Representation of the NVP−SA cocrystal asymmetric unit at
room temperature (inversion center indicated by a yellow dot and
hydrogen bond interactions as dashed blue lines). Thermal ellipsoids
drew at the 50% probability level.
Figure 5. Comparison of the SA molecule position in the NVP−SA
structures at room temperature (white) and at 100 K (gray).
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Nevirapine molecules in the NVP−SA structure form
homodimers through amide−amide interactions that display a
motif with graph set R2,2(8). In NVP−4HBZC, a hydrogen
motif with the same graph set R2,2(8) is also observed, but it
corresponds to a hydrogen bond motif formed between the
carboxylic acid in 4HBZC and the amide group in NVP,
displaying heterodimers.
If we compare the crystal packing that displays pure
nevirapine in PAHBIJ0138 with the nevirapine molecules
packing in the NVP−SA and NVP−4HBZC cocrystal
structures, the observed infinite pyridine stacking (π···π
interactions) of nevirapine molecules observed in PABHIJ01
is also conserved in NVP−SA and NVP−4HBZC cocrystals
(Figure 8). Furthermore, if we consider in the strong amide−
amide hydrogen bonds, these chains grow into mimic layers for
PABHIJ01 and NVP−SA (Figure 8d). NVP−4HBZC does not
present homodimers and therefore does not form these layers.
However, the cocrystal reported by Caira et al. of NVP and SAC
(LATQOO)17 also presents mimic 1D infinite chains and 2D
layers in its crystal structure. The way in which these layers are
packed in the crystal is different, while in the PABHIJ01
structure there are no holes; in NVP−SA and NVP−SAC
(LATQOO) cocrystals, the layers pack forming parallel pipes
that allow the SA and SACmolecules to be located forming tapes
(Figure 9 and Figure S8).
Justified by the fact that SA molecules are situated in pipe-
shaped channels along with the NVP cocrystal structure, we
propose a dynamic disorder at the RT structure. Salicylic acid
molecules rotate 180° synchronously along with the crystal
probably due to the low energy barrier between both
conformations, while, SA molecules are not able to present
dynamic effects in the crystal at 100 K. This disorder can also
explain the Caira et al. structure recorded at the CSD with
LATQUU refcode,17 which presents the same unit cell and
space group as our structure at low temperature. Both data were
collected at 100 K; however, the experiments were carried out in
a different manner. We kept the crystal mounted at the
goniometer head during the cooling ramp, while in LATQUU,
the crystal was frozen instantly. This can obviously make a
difference; a ramped temperature allows a conformational
selection, while fast freezing does not. In addition, rapid freezing
produces a disorder in the salicylic acid molecule, showing two
orientations: the major, presenting a final refined site occupancy
factor of 0.74, coinciding with the observed in our LT structure;
and the minor, with occupancy of 0.26, which is suggested as a
possible “intermediate state” (Figure 9).
Powder Dissolution Profile and Intrinsic Dissolution
Rate (IDR). As the cocrystals, eutectic systems can present
advantages over the pure drug. In order to evaluate the impact of
Figure 6. Representation of the NVP−SA cocrystal asymmetric unit at
100 K (hydrogen bond interactions depicted as dashed blue lines).
Thermal ellipsoids drawn at the 50% probability level.
Figure 7. Representation of the NVP−4HBZC cocrystal asymmetric
unit (hydrogen bond interactions depicted as dashed blue lines).
Thermal ellipsoids drawn at the 50% probability level.
Figure 8. Crystal structure of (a) pure nevirapine, PABHIJ01, (b) NVP−SA at 100 K and (c) NVP−4HBZC. Red dotted ellipses round infinite NVP
chains and zigzag dashed green lines frame the nevirapine layers that are common into PABHIJ01 andNVP−SA packing. (d) Perpendicular projection
of a nevirapine layer for the PABHIJ01 compound. Superposition of nevirapine chains for the structures: (e) PABHIJ01 (yellow) andNVP−SA (gray),
(f) PABHIJ01 (yellow) and 4HBZC (gray).
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eutectic systems in the dissolution properties, the powder
dissolution profiles and the intrinsic dissolution rates of pure
NVP, NVP−THEO, and NVP−CAF in water and 0.1 N HCl
medium were determined (Figure 10).
Figure 9. Structure of NVP−SA showing the pipe-shaped voids in yellow and on the right, the extended projection of the observed SA tapes that fit in
those channels for the three discussed NVP−SA cocrystals.
Figure 10.Dissolution profile of NVP in eutectic systems in comparison to pure NVP at 0.1 NHCl and water. Intrinsic dissolution rates of NVP in the
same samples were also determined for the same dissolution media.
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In the 0.1 N HCl medium, while pure NVP takes more than
80 min to dissolve 80% of its initial amount, NVP−THEO takes
less than 20min andNVP−CAF takes less than 5min to dissolve
the same amount. These results clearly show that the eutectics
exhibit an advantage with respect to the pure NVP relative to the
dissolution kinetics. In water, this advantage is even greater.
While less than 5% of pure NVP dissolves over 2 h, eutectic
materials reach 40% of dissolved material in less than 20 min for
NVP−THEO and in less than 5 min for NVP−CAF.
Although IDR was considered a parameter relevant for the
biopharmaceutical classification system in the past,39,40 the
literature indicates that nowadays it is been more relevant as a
solid-state characterization technique.41,42 As previously de-
scribed, all the samples show different crystal structures, and so
the intrinsic dissolution behavior was expected to be different
too. All the samples presentedR2 values higher than 0.9, showing
that no transition occurred during the test. Moreover, just
dissolution values of less than 10% were considered to plot the
results. Both modifications, with THEO and CAF, showed IDR
higher than that of the pure raw material.
So, both dissolution tests proposed here can be used to
discriminate between the raw material and the prepared samples
and also between these two modifications made. It can be
concluded that the modifications were successful in the
generation of higher dissolution rate structures.
■ CONCLUSIONS
In the attempt to improve the physicochemical properties of the
antiretroviral nevirapine, we have chosen seven compounds to
search for NVP multicomponents. They have been chosen
because of their possible ability to alter the interactions observed
in the packing arrangement of pure NVP because these
molecules contain carboxylic acid, amide, and planar electron-
delocalized fragments in their formula. The multicomponent
samples were characterized through solid-state techniques, and
the results indicate that our initial criterium was quite right, and
four cocrystals (NVP−SA, NVP−SAC, NVP−3HBZC, NVP−
4HBZC), two eutectics (NVP−THEO, NVP−CAF), and one
(NVP−URE) physical mixture were identified. Moreover, we
have used the multicomponent prediction tools available in the
CSD to confirmwhether they can be helpful in this type of study.
Results have shown they are adequate. Molecular complemen-
tarity (MC) tool establishes all coformers as suitable to form
cocrystals or multicomponents with NVP except for urea. With
the hydrogen bond propensity (HBP) tool, a high probability of
obtaining cocrystals for SA, 3HBZC, and 4HBZC is predicted;
for SAC, THEO, and URE the probabilities are almost nil, and,
in the case of CAF, the results show incompatibility to form
cocrystals with NVP.
Even though the methodology used to achieve the multi-
component structures is different from those used by Caira
(reference), the same crystalline phase was obtained for NVP−
SA and NVP−SAC as the one reported in the literature.
Moreover, the NVP−SA structures obtained in this work and
their comparison with LATQUU allowed us to identify a
temperature-dependent dynamic disorder behavior of the
salicylic acid molecules along the channels displayed in the
NVP host crystal. Further studies are required, and they will be
presented in a future manuscript.
NVP−THEO and NVP−CAF results comply with the
formation of eutectics since two different phases and a single
melting point were determined. In order to start understanding
the behavior of these two systems, phase diagrams were
obtained. Also, the composition and melting point of these
eutectics were determined. Moreover, dissolution studies have
demonstrated an improvement in the dissolution kinetics
behavior of these materials compared to pure NVP, especially
in the aqueous medium.
Finally, once again multicomponent materials are presented
as a good strategy to improve the properties of pharmaceutical
drugs, and knowledge-based methods are useful tools for
selecting molecules with the highest probability of crystallizing
with an API.
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Cient ı fícas for funding Pro ject ICOOPA2015 -
COOPA20094. D.C.-L. acknowledges Ministerio de Ciencia,
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(26) Fab́iań, L. Cambridge Structural Database Analysis of Molecular
Complementarity in Cocrystals. Cryst. Growth Des. 2009, 9 (3), 1436−
1443.
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